You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Twitter Demographics
Mendeley readers
Attention Score in Context
| Title |
Management of brain metastasis with magnetic resonance imaging and stereotactic irradiation attenuated benefits of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer
|
|---|---|
| Published in |
BMC Cancer, August 2015
|
| DOI | 10.1186/s12885-015-1593-2 |
| Pubmed ID | |
| Authors |
Yuichi Ozawa, Minako Omae, Masato Fujii, Takashi Matsui, Masato Kato, Shinya Sagisaka, Kazuhiro Asada, Masato Karayama, Toshihiro Shirai, Kazumasa Yasuda, Yutaro Nakamura, Naoki Inui, Kazunari Yamada, Koshi Yokomura, Takafumi Suda |
| Abstract |
Magnetic resonance imaging (MRI) enables a more sensitive detection of brain metastasis and stereotactic irradiation (SRI) efficiently controls brain metastasis. In limited-stage small cell lung cancer (LS-SCLC), prophylactic cranial irradiation (PCI) in patients with good responses to initial treatment is recommended based on the survival benefit shown in previous clinical trials. However, none of these trials evaluated PCI effects using the management of brain metastasis with MRI or SRI. This study aimed to determine the effects of MRI and SRI on the benefits of PCI in patients with LS-SCLC. The clinical records of pathologically proven SCLC from January 2006 to June 2013 in facilities equipped with or had access to SRI in Japan were retrospectively reviewed. Patients with LS-SCLC and complete or good partial responses after initial treatment were included in the study and analyzed by the Kaplan-Meier method. Of 418 patients with SCLC, 124 met criteria and were divided into patients receiving PCI (PCI group; n = 29) and those without PCI (non-PCI groups; n = 95). At baseline, ratios of patients with stage III were significantly advantageous for the non-PCI group, although younger age and high ratios of complete response and MRI confirmed absence of brain metastasis were advantageous for the PCI group. Neither median survival times (25 vs. 34 months; p = 0.256) nor cumulative incidence of brain metastasis during 2 years (45.5 vs. 30.8 %; p = 0.313) significantly differed between the two groups. Moreover, these factors did not significantly differ among patients with stage III disease (25 vs. 26 months; p = 0.680, 42.3 vs. 52.3 %; p = 0.458, respectively). PCI may be less beneficial in patients with LS-SCLC if the management with MRI and SRI is available. |
Twitter Demographics
The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 2% |
| Unknown | 43 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 14% |
| Other | 4 | 9% |
| Student > Ph. D. Student | 4 | 9% |
| Student > Master | 4 | 9% |
| Student > Postgraduate | 2 | 5% |
| Other | 7 | 16% |
| Unknown | 17 | 39% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 41% |
| Nursing and Health Professions | 3 | 7% |
| Unspecified | 1 | 2% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Social Sciences | 1 | 2% |
| Other | 1 | 2% |
| Unknown | 19 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 June 2016.
All research outputs
#17,770,433
of 22,824,164 outputs
Outputs from BMC Cancer
#4,963
of 8,301 outputs
Outputs of similar age
#177,640
of 263,348 outputs
Outputs of similar age from BMC Cancer
#90
of 143 outputs
Altmetric has tracked 22,824,164 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,301 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,348 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 143 others from the same source and published within six weeks on either side of this one. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.